Last update Oct. 9, 2016
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Finasteride in other languages or writings:
Finasteride belongs to these groups or families:
Main tradenames from several countries containing Finasteride in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 63 - 80 | % |
Molecular weight | 373 | daltons |
Protein Binding | 90 - 93 | % |
VD | 1.1 | l/Kg |
Tmax | 1 - 2 | hours |
T½ | 4.8 - 6 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Inhibitor of 5-α reductase enzyme that induces the pass of testosterone to dihydrotestosterone which has a greater androgenic effect.
Indicated for treatment of benign prostatic hypertrophy.
Not authorized for use in women although it is used for treatment of hirsutism with same or greater efficacy than Spironolactone or Flutamide (Moghetti 2000), androgenetic alopecia (Shum 2002) and Polycystic Ovary Syndrome (Lakryc 2003) .
At latest update no published data on excretion into breast milk were found.
Its high plasma protein-binding capacity makes it unlikely the excretion of significant amounts into breastmilk.
Not alterations on prolactin level have been reported.
A known and safer alternative should be preferred until more published data on this drug related to breastfeeding is available within the first 6 mo after birth, especially during the neonatal period and in case of prematurity.
Exposure through breastmilk may be minimized by waiting at least 6 hours before resuming breastfeed after the last dose of drug.